HK Stock Market Move | HENLIUS (02696) rose more than 14% in the afternoon, HANBEITAI recently approved overseas, the company's globalization process is accelerating.

HENLIUS (02696) rose more than 14% in the afternoon, with the stock price rising more than 60% in the past month. As of the time of writing, it rose 14.19% to HKD 26.55, with a trading volume of HKD 91.96 million. In terms of news, recently, HENLIUS' independently developed and produced Hanbeite (Bevacizumab injection) has officially been approved for listing by the Bolivian National Drug and Health Technology Administration. This milestone marks Hanbeite as the fourth independently developed and produced product by HENLIUS to be approved for listing overseas, following Hanquyou (Rituximab), H drug Hanzhuang (Sulilumab), and Hanlikang (Rituximab). further promoting the company's globalization process. Previously, HENLIUS announced a licensing agreement with Dr. Reddy's, under which the company granted Dr. Reddy's a license to develop, produce, and commercialize HLX15 (recombinant anti-CD38 human monoclonal antibody injection) intravenous and subcutaneous injection formulations in the United States and designated European regions and territories. According to the terms of the agreement, HENLIUS will be responsible for the research and development, production, and commercial supply of HLX15, and will receive $131.6 million from the transaction, with $33 million as the upfront payment.